BRAIN DERIVED NEUROTROPHIC FACTOR BDNF LEVELS IN DEPRESSED WOMEN TREATED WITH OPEN-LABEL ESCITALOPRAMReportar como inadecuado




BRAIN DERIVED NEUROTROPHIC FACTOR BDNF LEVELS IN DEPRESSED WOMEN TREATED WITH OPEN-LABEL ESCITALOPRAM - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Psychiatria Danubina, Vol.25 No.2 June 2013. -

Background: Recent studies suggest the important role of brain derived neurotrophic factor BDNF in the etiopathogenesis of

major depressive disorder MDD and the mechanism of action of antidepressants. This study aimed to correlate serum levels of

BDNF and clinical symptoms in patients with MDD before and after 6 months treatment with escitalopram.

Subjects and methods: Twenty women diagnosed with MDD and 20 aged-matched healthy female controls were recruited. The

patients received escitalopram 10-20 mg-day. BDNF serum levels were measured at inclusion, week 4, week 12 and week 24. The

Montgomery-Åsberg Depression Rating Scale MADRS was used to assess the severity of depressive symptoms and the clinical

evolution of patients. Statistical analysis was performed using both observed cases and last observation carried forward.

Results: At baseline, low serum levels of BDNF were associated with MDD. In women with MDD, escitalopram seems to have a

positive effect on BDNF serum levels in parallel with the clinical response.

Conclusions: This study suggests that a good clinical evolution under treatment with escitalopram might be associated with

increases of BDNF levels in female patients.

brain derived neurotrophic factor – BDNF – depression - escitalopram



Autor: Maria Ladea - ; Clinical Psychiatric Hospital -Prof. Dr. Alexandru Obregia-, Bucharest, Romania Mihai Bran - ; Clinical Psychiatr

Fuente: http://hrcak.srce.hr/



DESCARGAR PDF




Documentos relacionados